18F-PSMA PET/CT scan for PSMA-positive tumors
Part of Cancer clinical trials.
This Phase 2 study tests an imaging scan called 18F-PSMA PET/CT to find tumors that have a specific marker (PSMA). It may help doctors better locate and evaluate PSMA-positive cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have (or your doctors suspect) a PSMA-positive tumor, such as prostate cancer or certain other cancers.
- You are able and willing to follow the study instructions and cooperate with the study visits.
- You can sign informed consent (your permission to join).
- You do NOT have major serious conditions affecting the brain/nervous system, gut, heart, liver, kidneys, blood, hormones/endocrine system, lungs, or immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how well a special type of PET/CT scan (called PSMA PET/CT) can see cancer in people who have or may have certain tumors. It may help doctors better understand and track the disease.
This study looks at how well a special scan (PSMA PET/CT) works for people with cancers other than prostate cancer. If your doctor already scheduled this scan for your care, you may be able to help researchers learn more about its accuracy.
This study uses a special type of PET scan called PSMA PET to better understand and track prostate cancer. The scan helps doctors see where the cancer is in the body and if treatment is working.
This study looks at a PSMA-targeted PET/CT scan using 68Ga-PSMA-617 for tumors that show a specific marker (PSMA). It’s meant to help confirm or evaluate suspected or known PSMA-expressing tumors in real-life clinical practice.
This trial compares two types of PET/CT scans (using different radioactive tracers) to see which is better at finding prostate cancer, tracking its return, or spotting spread. It's for people with prostate cancer or those being checked for recurrence after treatment.
This Phase 3 study checks whether a PSMA PET/CT scan (using a special tracer) can help doctors make better decisions for people with prostate cancer after treatment, based on PSA blood test changes. It may help identify whether cancer has spread or how to plan next steps.
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.